SCHEMBL8033425

SCHEMBL8033425

CCN1/C(=C/C(O)c2cccc(Cl)c2)Sc2ccc(OC)cc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
HSD17B10 Q99714 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HTT P42858 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 1/20 0.56
DYRK1A Q13627 6/20 0.54
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
CLK1 P49759 4/20 0.54
BLM P54132 3/20 0.54
LMNA P02545 3/20 0.54
PIM1 P11309 2/20 0.54
CSNK1D P48730 2/20 0.54
CSNK1E P49674 2/20 0.54
CLK3 P49761 2/20 0.54
CSNK1G2 P78368 2/20 0.54
MAP3K19 Q56UN5 2/20 0.54
PIM3 Q86V86 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8035944 0.88 DYRK1A (0.60) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL8030001 0.80 MEN1 (0.66) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL8020265 0.77 MEN1 (0.62) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL8030185 0.75 HSD17B10 (0.64) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL8033454 0.75 MEN1 (0.53) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL24534821 0.73 DYRK1A (0.70) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL24718937 0.72 MAPT (1.00) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL2977830 0.71 DYRK1A (1.00) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL2977826 0.71 DYRK1A (1.00) MAPTHSD17B10ALDH1A1HTTNPSR1
SCHEMBL4157023 0.70 DYRK1A (0.76) MAPTHSD17B10ALDH1A1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009085226-A2 INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF SIRTRIS PHARMACEUTICALS, INC. (US) 2009-07-09 WO disclosed